Teva

Teva reports top-line results from phase III MS trial

Monday, June 18, 2012 03:30 PM

Teva Pharmaceutical, an Israel-based global pharmaceutical company, released positive top-line results from the GALA (Glatiramer Acetate Low-Frequency Administration) phase III trial showing that 40mg/1ml glatiramer acetate injection (GA) significantly reduced multiple sclerosis (MS) disease activity, while maintaining a favorable safety and tolerability profile.

More... »

Teva Canada sells Quebec facility to Halo Pharmaceutical

Monday, April 2, 2012 11:01 AM

Teva Canada has finalized an agreement under which Halo Pharmaceutical, a contract manufacturing organization based in Whippany, N.J., will acquire Teva's manufacturing facility in Mirabel, Quebec.

More... »

FDA approves BioSante’s Bio-T-Gel

Wednesday, February 15, 2012 03:59 PM

The FDA has approved Bio-T-Gel for the treatment of male hypogonadism (low testosterone levels), according to BioSante Pharmaceuticals.

More... »

Results of OncoGenex phase I/II Custirsen trial published

Friday, January 6, 2012 09:32 AM

OncoGenex Pharmaceuticals has reported results of a phase I/II study to determine the effectiveness of its investigational compound custirsen in conjunction with a gemcitabine/platinum-based regimen in patients with advanced non-small cell lung cancer (NSCLC).

More... »

Teva invests in $300M Philadelphia distribution center

Tuesday, September 27, 2011 01:00 PM

Generic drug giant Teva Pharmaceutical, after years of a dramatic and sometimes controversial process to select a new home for its distribution center, is breaking ground on a $300 million building off Red Lion Road in Philadelphia, according to the Philadelphia Business Journal.  

More... »

Celniker and Schor join Eleven Biotherapeutics

Friday, September 23, 2011 11:09 AM

Eleven Biotherapeutics, a biopharmaceutical company focused on engineering and developing protein-based therapeutics, has named Abbie Celniker, Ph.D., chief executive officer.

More... »

Teva aquires Taiyo Pharmaceuticals

Monday, May 16, 2011 12:52 PM

Israel-based Teva Pharmaceutical will acquire a controlling stake in Japan-based generics firm Taiyo Pharmaceutical, according to Pharma Times.

More... »

Teva aquires Cephalon

Monday, May 2, 2011 01:01 PM

Teva Pharmaceutical and Cephalon have unanimously approved a definitive agreement under which Teva will acquire all of the outstanding shares of Cephalon for $81.50 per share in cash, or a total enterprise value of approximately $6.8 billion. The transaction is not conditioned on financing and is expected to be completed in the third quarter of 2011.

More... »

Teva, Biogen reveal positive results for MS drugs

Wednesday, April 13, 2011 12:49 PM

Teva and Biogen Idec have presented late-stage data on their respective oral offerings for the treatment of multiple sclerosis (MS), according to Pharma Times.

More... »

Teva: Doctors being contacted for trial of Copaxone copy

Wednesday, March 9, 2011 01:34 PM

Doctors are being contacted to organize a clinical trial for a copy of Teva Pharmaceutical’s multiple sclerosis medicine Copaxone, according to a report in FiercePharma.

More... »